Telek Hande Hüsniye, Doluoglu Omer Gokhan, Burcu Ayse, Demirok Gulizar, Ornek Firdevs, Ayyildiz Ali
Department of Ophthalmology Clinic, Ankara Training and Research Hospital, Ankara, Turkey.
Department of Urology Clinic of Ankara Training and Research Hospital, Sukriye Mahallesi, Ulucanlar Caddesi, No:89, 06340, Ankara, Turkey.
Ther Adv Urol. 2017 Apr 11;9(5):91-97. doi: 10.1177/1756287217701861. eCollection 2017 Oct.
To evaluate the effects of tolterodine on anterior segment and choroidal thickness by using the Pentacam system and optical coherence tomography (OCT) (Pentacam).
A total of 122 eyes of 61 patients (34 female; 27 male) were included in the study. All patients underwent a regular ocular examination and intraocular pressure measurements before and after 3 months of antimuscarinic drug tolterodine treatment, in addition, pupil diameter, anterior chamber depth, anterior chamber volume, anterior chamber angle, and lens thickness were measured through Pentacam (Oculus Inc., Wetzlar, Germany) system. Measurements of choroidal thickness were performed by OCT (Spectralis, Heidelberg Engineering, Heidelberg, Germany).
The mean age was 58.4 ± 7.3 years and 56.5 ± 11.1 years for female and male patients. The mean intraocular pressure was 15.10 ± 2.75 mmHg before treatment and 15.18 ± 2.65 mmHg after treatment. Pupil diameters were 3.09 ± 0.48 mm before treatment and 3.12 ± 0.43 mm after treatment. Anterior chamber depth, before and after treatment were 2.68 ± 0.65 mm and 2.70 ± 0.61 mm. The mean value for subfoveal choroidal thickness was 267.92 ± 81.35 μm before the administration of tolterodine, whereas the mean choroidal thickness was 271.83 ± 75.42 μm after the administration of tolterodine. The alterations in the subfoveal choroidal thickness were not statistically significant ( = 0.862).
After 3 months of therapy with tolterodine, there were no significant changes in anterior segment parameters and choroidal thickness.
使用Pentacam系统和光学相干断层扫描(OCT)(Pentacam)评估托特罗定对眼前节和脉络膜厚度的影响。
本研究共纳入61例患者(34例女性;27例男性)的122只眼。所有患者在抗毒蕈碱药物托特罗定治疗3个月前后均接受常规眼部检查和眼压测量,此外,通过Pentacam(德国韦茨拉尔奥culus公司)系统测量瞳孔直径、前房深度、前房容积、前房角和晶状体厚度。脉络膜厚度测量采用OCT(德国海德堡海德堡工程公司Spectralis)。
女性和男性患者的平均年龄分别为58.4±7.3岁和56.5±11.1岁。治疗前平均眼压为15.10±2.75 mmHg,治疗后为15.18±2.65 mmHg。治疗前瞳孔直径为3.09±0.48 mm,治疗后为3.12±0.43 mm。治疗前后前房深度分别为2.68±0.65 mm和2.70±0.61 mm。托特罗定给药前黄斑下脉络膜厚度的平均值为267.92±81.35μm,而托特罗定给药后脉络膜厚度的平均值为271.83±75.42μm。黄斑下脉络膜厚度的变化无统计学意义(=0.862)。
托特罗定治疗3个月后,眼前节参数和脉络膜厚度无明显变化。